Therapy is centered on wound care, treatment of secondary infection, and the addition of local or systemic immunosuppressive therapy. In mild cases, local topical therapy may prove effective, including cromolyn sodium, calcineurin inhibitors, or superpotent corticosteroids or intralesional corticosteroids. However, most patients will require systemic treatment, and medium- to high-dose corticosteroids are traditionally used as initial therapy. Frequently, a corticosteroid-sparing agent is used to ameliorate the adverse effects associated with systemic corticosteroid use. To our knowledge, only one placebo-controlled blinded study has been performed in patients with PG. Brooklyn et al7 evaluated the use of infliximab vs placebo in patients with PG and found that 46% of patients in the infliximab arm had improved at 2 weeks compared with 6% who received placebo. Otherwise, case series and individual case reports dominate the literature and have detailed the usefulness of cyclosporine, azathioprine, methotrexate, etanercept, adalimumab, tacrolimus, plasmapheresis, intravenous immunoglobulin, cyclophosphamide, chlorambucil, dapsone, interferon alfa, clofazimine, and mycophenolate mofetil.3,8- 10 Herein, we discuss our experience in a series of 7 patients with PG who were treated with mycophenolate mofetil.